

31st Annual Cancer Progress Goes Virtual for 2020, May 5 & 6

May 5, 2020

9:00 – 9:15 am

Opening Remarks

Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

9:15 – 10:00 am

Keynote: Breaking the Ice on the "Cold" Tumor Microenvironment

Speaker: Michael A Curran, PhD, Associate Professor, Dept. of Immunology
Scientific Director, ORBIT Platform, The University of Texas MD Anderson Cancer Center, Department of Immunology, Division of Basic Sciences

10:15 – 11:30 am

Paradigm-shifting platforms I, IO: Taking IO to the next Level

Moderator: Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting

Panelists:

- Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
- Frank Borriello, MD, PhD, Founder & CEO, Alloplex Biotherapeutics Inc.
- Mary Haak-Frendscho, PhD, President & CEO, Spotlight Therapeutics
- Laurent Levy, PhD, CEO Nanobiotix
- Ulrik Nielsen, PhD, CEO, Tidal Therapeutics
- Lini Pandite, MD, CMO, Shattuck Labs, Inc.
- Sijme Zeilemaker, COO, Immunicum

11:45 – 1:00 pm

Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable

Moderator: James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

Panelists:

- Robert A Copeland, PhD, President & CSO, Accent Therapeutics, Inc.
- Chris LeMasters, Former EVP and CBO, Mirati Therapeutics
- Vicky Richon, PhD, President & CEO, Ribon Therapeutics
- Mark Rolfe, PhD, SVP, BMS
- Tingting Zhang-Kharas, PhD, Oncology External Innovation Advisor, Loxo Oncology at Lilly

1:00-1:30 pm

Break for Lunch

1:30 – 2:45 pm

Investing into Oncology: Who, What and Where?

Moderator: Mark Simon, Partner and Co-Founder, Torrey

Panelists:

- Michele Cleary, PhD, CEO, The Mark Foundation for Cancer Research
- Michael Gladstone, Principal, Atlas Venture
- Michael G. King Jr., Entrepreneur in Residence, Fortress Biotech Inc.
- Christoph Lengauer, PhD, MBA, Partner, Third Rock Ventures
- Vanessa Lucey, PhD, MBA, Director, CRI Venture Fund & Clinical Accelerator, Cancer Research Institute
- Bibhash Mukhopadhyay, PhD, Principal, NEA
- Michal Silverberg, MBA, Managing Director, Novartis Venture Funds

3:00 – 4:15 pm

Vaccines: From Paleo to Neo, Cancer Vaccines in the New Age of IO

Moderators: Jeffrey M. Bockman, PhD, EVP, and Serom Lee, PhD, Consultant, Cello Health BioConsulting

Panelists:

- Andrew Allen, MD, PhD, President & CEO, Gritstone Oncology, Inc.
- Gad Berdugo, Msc., Eng. MBA, CEO, EpiVax Oncology, Inc.
- Nina Bhardwaj, MD, PhD, Director of Cancer Immunotherapy, Professor of Medicine, The Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai
- Chip Clark, President & CEO, Genocea Biosciences
- Erik Digman Wiklund, PhD, CBO, Targovax
- Mai-Britt Zocca, PhD, CEO, IO Biotech

4:30 – 5:45 pm

Inflecting Value in Early Stage Biotech: Linking Proof of Relevance to Pricing & Reimbursement

Moderator: Ed Saltzman, Executive Chairman, Cello Health BioConsulting

Panelists:

- Robert Glassman, MD, Vice-Chairman, Global Health Care Investment Banking, Credit Suisse; Clinical Assistant Professor, Division of Hematology-Oncology, Weill-Cornell Medical College
- Anna Kaltenboeck, MA, Senior Health Economist & Program Director for the Center for Health Policy and Outcomes, and the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center
- Michael Kolodziej, MD, VP and CIO, ADVI Health
- David Weinstein, MSc, Senior Director, Bristol-Myers Squibb

5:45 pm

Day 1 Cancer Progress 2020 Conference Conclude

May 6, 2020

9:00 – 9:15 am

Opening Remarks: Review of Day 1

Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

9:15- – 10:30 am

Next Wave of Diagnostics, Including Precision IO: Early and Smarter, the Better to Cure

Moderator: Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research

Panelists:

- David Fabrizio, VP, Translational Strategy, Foundation Medicine, Inc
- Colin Hill, CEO, Co-founder & Chairman, GNS Healthcare, Inc.
- Christoph Lengauer, PhD, MBA, Chief Innovation Officer, Thrive Earlier Detection Corp.
- Jimmy Lin, MD, PhD, MHS, CSO, Freenome
- Adam G. Marsh, PhD, CSO & CO-Founder, Genome Profiling, LLC
- Tariq Sethi, MD, PhD, CSO, Oncimmune

Advanced Therapeutics

10:45- 12:00 pm

Antigen/platform pairings (“Forget Wine and Cheese...Get this Right and Your Valuation Takes Flight”)

Moderator: Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Sharon Benzeno, PhD, MBA, Chief Business Development Officer, Adaptive Biotechnologies Corp
- Travis Quigley, VP, Clinical Development, Arcellx, Inc.
- Henry Rath, CBO, TScan Therapeutics
- Stephen Rubino, PhD, CBO, Celyad
- Ian Somaiya, CFO, TCR2 Therapeutics Inc.

12:00- 12:30

Break for Lunch

12:30- 1:45 pm

State of the union for off-the-shelf (“In an ‘Allo or Bust’ Market, What’s Rising to the Top of the Shelf?”)

Moderator: Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Robert Ang, MD, MBA, President & CEO, Vor BioPharma Inc.
- Jim Beitel, MD, PhD, SVP, Corporate Development, Fate Therapeutics Inc
- Thomas J. Farrell, President & CEO, Artiva Biotherapeutics
- Maksim Mamonkin PhD, Assistant Professor, Pathology & Immunology Center for Cell and Gene Therapy, Baylor College of Medicine
- Gary Shapiro, PhD, Director of Immuno-Oncology Research, Takeda Pharmaceuticals
- Arthur Stril, VP Corporate Development, Cellectis

2:00 – 2:30 pm

Fireside Chat with Samit Hirawat, MD, CMO, Bristol-Myers Squibb

2:45 – 4:00 pm

What are investors and partners looking for today (“How to Stand Out/Inflect Value in a Frothy Vat of Cells”)

Moderator: Paul D. Rennert, President & Chief Scientific Officer, Aleta Biotherapeutics

Panelists:

- John Delyani, PhD, MBA, VP Corporate Development, Tmunity Therapeutics Inc
- Stanley Frankel, MD, SVP, Cellular Therapy, Bristol-Myers Squibb
- Lee Greenberger, MD, PhD, SVP & CSO, Leukemia & Lymphoma Society
- Michael Kalos, PhD, EVP and Head of R&D, Arsenal Biosciences
- Michael G. King Jr., Entrepreneur in Residence, Fortress Biotech Inc.
- Sharon Rooney-Mayer, Executive Director, Global Disease Strategy Lead Cell and Gene Therapies, Novartis Oncology
- Mark Simon, Partner and Co-Founder, Torreya

4:15 – 5:30 pm

Strategic Considerations in ACT Manufacturing (“From Here to There, and Back Again”)

Moderator: Steven A. Feldman, Ph.D. Director, Manufacturing and Process Development, Center for Cancer Cell Therapy, Stanford Cancer Institute/ Stanford School of Medicine

Panelists:

- Eytan Abraham, Head of Personalized Medicine, Lonza Pharma & Biotech
- Kim Nguyen, PhD, VP, CMC, Precision BioSciences, Inc.
- Sanjin Zvonić, PhD, VP, Product Development and Manufacturing, WindMIL Therapeutics Inc

5:45 – 7:00 pm

Oncology Modalities Facing Off: Room for Many or One to Rule them All?

Moderator: Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

Panelists:

- Michael DeRidder, PhD, VP, Medicine Commercialization Leader, Oncology Cell Therapy, GSK
- Michael Kalos, PhD, EVP and Head of R&D, Arsenal Biosciences
- Llew Keltner, MD, PhD, CEO, EPISTAT
- Jason B. Litten, MD, CMO, Artiva Biotherapeutics
- Vanessa Lucey, PhD, MBA, Director, CRI Venture Fund & Clinical Accelerator, Cancer Research Institute

7:00 pm

Cancer Progress 2020 Conference Concludes